HPM Partners »

Halozyme Therapeutics shares owned by HPM Partners

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by HPM Partners from 13F filings

Historical chart of HPM Partners investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by HPM Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by HPM Partners

Quarter filed Position value Share count Share price at filing
2023-12-31 $37k 43k 0.86
2023-09-30 $36k 43k 0.84
2023-06-30 $36k 43k 0.84
2022-12-31 $42k 43k 0.97
2022-09-30 $37k 43k 0.86

More positions owned by HPM Partners

Vanguard Index Fds Ex Trd Eq Fd (VOO)
Apple (AAPL)
Microsoft Corp Stock (MSFT)
Procter And Gamble Stock (PG)
Spdr S&p 500 Etf Tr Equity (SPY)
Ishares Tr Ex Trd Eq Fd (IVV)
Vanguard Tax-managed Fds Equity (VEA)
Ishares Tr Etf (IEFA)
Credit Accep Corp Mich Stock (CACC)
Amazon Stock Put Option (Principal) (AMZN)
Ishares Tr Etf (QUAL)
Nvidia Corporation Stock (NVDA)
Schwab Strategic Tr Equity (SCHX)
Alphabet Equity (GOOGL)
Alphabet Equity (GOOG)

View all positions for HPM Partners

Top funds holding Halozyme Therapeutics

Wellesley Investment Advisors
Davidson Kempner Capital Management
Lazard Asset Management
Citigroup
Aviva
Citadel Advisors
D. E. Shaw & Co
Wells Fargo & Company
Readystate Asset Management
Tenor Capital Management
Wolverine Asset Management
Victory Capital Management
Jpmorgan Chase & Co
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Shenkman Capital Management

View all funds holding Halozyme Therapeutics